Log in
Biocatalysts provide unique activities that facilitate chemical transformations that are simply not possible using abiotic methods. Northumbria University researchers with expertise in enzymes and biocatalysis have provided biocatalysis services to the pharmaceutical, fine chemical, food and biofuels industries through our business facing innovation unit Nzomics. This has generated significant contract research, collaboration and licence agreements to companies, including the pharmaceutical company GlaxoSmithKline and the services-led company Almac. Biocatalysts produced as a result of Northumbria University research and technology transfer are sold worldwide and benefit business through their use in research and development activities, such as the production of intermediates in drug synthesis.
Bio Nano Consulting (http://www.bio-nano-consulting.com) was established as an operating business in 2007 through a joint venture between Imperial College London and UCL, whose formation was underpinned by research produced by Professor Tony Cass's group at Imperial. The company is the first consultancy in Europe to focus on the increasingly important intersection between bio- and nanotechnology, and it facilitates the development and commercialisation of new biomedical and nanotechnology-based techniques. Since its start-up, the company has attracted numerous clients across the aerospace and diagnostics sectors, including Lockheed-Martin and [text removed for publication]. The company's activities have generated £6M worth of revenue and it has a growing portfolio. The company, which is based in London, currently has 8 full time employees.
Plaxica is a spin-out from, and based, at Imperial College London with economic, societal and environmental impacts. Launched in 2008, Plaxica is a process technology licensing business which is tackling the barriers that currently prevent a wider acceptance of bioplastics; specifically improving properties, decreasing cost and using non-food feedstocks to manufacture the biopolymer poly(lactic acid), PLA. Plaxica's technology uses sustainable feedstocks to produce PLA using more energy-efficient processes, to produce a strong, high-quality polymer, the result of which is a low-cost, environmentally-friendly biopolymer for use in applications including textiles, packaging, and automobile parts. In the REF period Plaxica has raised £10m from investors such as Imperial Innovations, Invesco Perpetual and NESTA Investments. The market pull for biorenewable materials from consumers is strong and the EU predicts that PLA will substitute >10% of the existing market for petrochemical polymers and forecasts a market >$15b [A].
Molecular Vision Ltd ("MV"), which was spun-out of Imperial Innovations, develops simple-to-use, point-of-care diagnostic devices (known as the BioLED™ platform) that quickly produce lab-quality information from a single sample of bodily fluids. Since 2008 MV has validated the platform, including demonstration of its CardioplexTM triple test for myoglobin, CK-MB and troponin-I in a serum sample, and undertaken >£1.5M of contract work for a variety of customers including Acrongenomics Inc, Microfluidic ChipShop and L'Oreal; addressing analysis problems relating to kidney and cardiac health, pathogen identification and cosmetics. During the REF period the Company has generated a total of over £3.4m in investment, contract revenue and non-UK grant funding and created greater than 50 man years of UK employment, primarily at the PhD level. Abingdon Health Group acquired a majority stake in MV in 2012 as part of its strategy to create a fully integrated business in the UK that is able to compete in the large and global immunodiagnostics market.
Molecular Vision Ltd (MV), an Imperial Innovations spinout, has developed a low-cost technology for multiplexed analysis on bodily fluids. The BioLED™ platform rapidly delivers lab-quality information from a single-sample point-of-care diagnostic device. Since 2008 MV has validated the platform, including demonstration of its Cardioplex™ triple test for myoglobin, CK-MB and troponin-I in a serum sample, and undertaken > £1.5M of contract work for a variety of customers including Acrongenomics Inc, Microfluidic ChipShop and L'Oreal. A further £1.2M in non-UK and £2.6M in UK equity investment and > £660K in non-UK grant funding has been injected via MV into the UK economy during the REF period, securing > 50 person years' employment. MV is now a key component of the Abingdon Health Group's (AHG's) strategy to create a fully integrated UK business to compete in the multi-billion pound global immunodiagnostics market. Agreements with a leading European pharmaceutical company and a large multi-national chemical company, in both cases to co-develop point-of-care diagnostic tests in the UK, are now underway.
Research carried out at Canterbury Christ Church University (CCCU) since 1998 has led to the establishment of the ladybird, Chilocorus nigritus, as a viable biocontrol agent (BCA) in UK glasshouses. However, integrated pest management (IPM) programmes involving C. nigritus sometimes inexplicably fail. The specific impact claimed here relates to research at CCCU, in collaboration with the Royal Botanic Gardens Kew and the Natural History Museum, which has improved the efficacy of utilising C. nigritus for biocontrol.
Specifically, this research has: 1) optimised protocols for growth and use of C. nigritus, 2) resulted in changes in practice at the Royal Botanic Gardens Kew, and 3) changed the advice given by the companies selling C. nigritus as a biocontrol agent.
Locust and grasshopper outbreaks can form swarms containing billions of insects, creating feared and damaging agricultural pests. Following research at Imperial College London, the entomopathogenic fungus Metarhizium acridum was developed into an oil formulated product (`Green Muscle®') that could be applied by ground-based and aerial spray equipment at ultra-low volume (ULV) rates, when locust and grasshopper populations periodically increased. Green Muscle® has since been used to treat locust outbreaks in Israel and five southern African countries. Green Guard®, an associated mycoinsecticide marketed in Australia, has been used extensively to control locusts in regions where there are land use limitations on chemical pesticides. Both Green Musclef6da and Green Guardf6da are supplied by Becker Underwood. Besides the success of Metarhizium as an effective, environmentally-friendly locust control option, substantial science and enabling technology ensued, that should accelerate the development of other mycopesticides as important alternatives to currently beleaguered chemical pest control methods.
A spin-out company, Ingenia Technology Ltd, was launched in 2005, to bring the technique now known as Laser Surface Authentication (LSA) to market. LSA is used to detect and prevent forgeries by allowing a unique, naturally occurring and uncopyable identity code to be read from material surfaces. It is particularly useful for fighting counterfeiting and smuggling of high-value documents and products and as such makes an important contribution to (i) industrial and consumer safety, (ii) commercial revenues and (iii) countering criminal activity. Organisations and companies contracted to use Ingenia's LSA technology include the pharmaceutical firm Bayer, carton manufacturers CARTONDRUCK and Grafiche Bramucci, Swiss precious metal refiner PAMP and the International Atomic Energy Agency.
Metamaterials deliver electromagnetic properties not available in natural materials. Transformation optics replaces the ray picture of Snell's law with the field lines of Maxwell's equations and is an exact description of classical optics. These powerful concepts, originally developed by Prof John Pendry, have engendered massive interest in the electromagnetic community encompassing radio frequency (RF) through to optical applications. His advice is sought by numerous companies and these concepts are now filtering through into products. In the last 5 years there has been great involvement of industry and particularly of the defence establishment in the USA who run several multi mullion dollar programs on metamaterials based at DARPA, WPAFB and Sandia. A company, KYMETA, was formed in 2012 to market this technology with $12M of investment funding, and is developing a laptop-sized antenna that gives instant Internet hotspot access anywhere in the world, with an ultimate application allowing cheap and fast Internet connections for the everyday consumer. In the UK, BAE Systems is using metamaterials for several applications including compact, directional antennas.
Essex research identified a novel bioprocessing matrix which has since been developed into commercial products and recently launched into external markets by Porvair Filtration Group Ltd. The discovery involved the chemical modification of sintered thermoplastic materials in order to attach biological molecules, so conferring highly specific functionalised properties to an otherwise inert base material. This enabled a new approach for protein immobilisation, having technical and practical advantages over existing processes. As a direct result, Porvair has adopted a new technology and invested £900k in R&D over eight years. Essex research has supported a change in business strategy, enabling entry into new markets, which has in turn both safeguarded and created jobs at Porvair.